MedTrace Logo

A Study to Determine if Aquamin Modulates Inflammatory Biomarkers in the Blood of Osteoarthritis and Healthy Subjects

NCT01321281 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2012-05-15

No results posted yet for this study

Summary

Osteoarthritis (OA) is the most common kind of arthritis and primarily affects the large, weight bearing joints (including the knees, lower back, hips, neck and the feet) and the joints in the hands. OA results from the breakdown of cartilage in joints, leading to joint pain and damage. It affects about 8 million people in the United Kingdom and nearly 27 million people in the United States, most of whom are over the age of 45.

This study aim to determine if Aquamin (as AquaCal and AquaPT) affects molecules of inflammation in the blood of osteoarthritis and healthy subjects.

Conditions

Interventions

DIETARY_SUPPLEMENT

AquaCal

AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg).

DIETARY_SUPPLEMENT

AquaPT

AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract.

Sponsors & Collaborators

  • Andrea Doolan

    lead OTHER

Principal Investigators

  • Timothy Dinan · University College Cork

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Ireland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01321281 on ClinicalTrials.gov